


PHARMACEUTICAL 2021

MEI Pharma Inc. Rank 159 of 409







PHARMACEUTICAL 2021

MEI Pharma Inc. Rank 159 of 409



The relative strengths and weaknesses of MEI Pharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MEI Pharma Inc. compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 96% points. The greatest weakness of MEI Pharma Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 59% points.

The company's Economic Capital Ratio, given in the ranking table, is -59%, being 296% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	208,644
Cost of Goods Sold	2,671
Intangible Assets	0
Liabilities, Current	23,304
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	1.0
Other Liabilities	108,206
Other Net Income	-21,475
Property and Equipment	1,084
Research and Development	34,065
Revenues	28,913
Selling, General and Administrative Expense	16,717

Output Variable	Value in 1000 USD
Assets	209,728
Liabilities	131,510
Expenses	53,454
Stockholders Equity	78,218
Net Income	-46,016
Comprehensive Net Income	-46,016
Economic Capital Ratio	-59%